Abstract: Levofl oxacin is a widely used fl uoroquinolone approved for the treatment of complicated urinary tract infections and acute pyelonephritis. A comprehensive review of the medical literature identifi ed fi ve publications evaluating levofl oxacin for the treatment of either complicated urinary tract infections or acute pyelonephritis. All trials, although variable in their inclusion criteria and levofl oxacin dosing strategies, reported microbiologic, clinical, and safety-related outcomes. High microbiologic eradication rates, ranging from 79.8% to 95.3%, were observed in all studies. Escherichia coli was the most commonly isolated uropathogen. Data on levofl oxacin resistance, both at baseline and after therapy, were limited. Clinical success was observed to range from 82.6% to 93% when measured after the completion of therapy. These clinical and microbiologic results were comparable to the fl uoroquinolone comparators in all trials. Insuffi cient data are available to evaluate the outcomes in any meaningful patient subgroups, including catheterized patients, and those with other specifi c complicating factors. Levofl oxacin was well tolerated in these studies, with headache, gastrointenstinal effects, and dizziness being the most commonly reported adverse events. The published data support the use of levofl oxacin in complicated urinary tract infections and acute pyelonephritis. Further trials are necessary to evaluate levofl oxacin within specifi c patient sub-populations.
Introduction
Urinary tract infections are one of the most frequently occurring bacterial infections. In the United States alone, they account for over 7 million offi ce visits and approximately 15% of community-prescribed antibiotics (Mazzulli 2001; Foxman 2002) . While the majority of these infections are uncomplicated, patients with complicated urinary tract infections (cUTI) are, by defi nition, at greater risk for adverse outcomes. Levofl oxacin, a widely-used fl uoroquinolone, was approved in the US for the treatment of cUTI and acute pyelonephritis (AP) in 1996 and, more recently, in 2008 a higher dose, short-course regimen was also approved for this indication. This review will examine the clinical data available to evaluate the effi cacy and safety of this antimicrobial for cUTI and AP.
Complicated urinary tract infections and pyelonephritis
Generally, a cUTI is considered to be an infection that occurs in the setting of any factor that predisposes to treatment failure or recurrence (McCue 1999) . However, no true consensus has been reached within the medical community as to what specifi cally defi nes a cUTI. Traditionally, urinary tract infections in patient populations such as those with diabetes mellitus, pregnant females, and males have been considered to be complicated infections (Anderson 1996) . Other descriptions of a cUTI have also included patients who are elderly, have experienced recent instrumentation or antimicrobial treatment, or possess functional or anatomic abnormalities of the genitourinary tract (Hooton and Stamm 1991) . Ronald et al proposed an alternate classifi cation scheme, in which a cUTI is characterized by the presence of structural abnormalities (urinary obstructions, neurogenic bladder, etc.), metabolic and/or hormonal abnormalities (diabetes mellitus, pregnancy, renal impairment, etc.), impaired host responses (transplant recipients, neutropenic patients, etc.), or infection with an unusual pathogen (including yeasts, fungi, and antimicrobial-resistant bacteria) (Ronald and Harding 1997 ). Mandell's Principles and Practice of Infectious Diseases defi nes cUTIs as urinary tract infections in men, pregnant women, children, hospitalized patients, and patients with functional or structural abnormalities of the urinary tract (Sobel and Kaye 2005) .
AP is commonly described as an infection of the upper urinary tract that encompasses fever and fl ank pain and/or tenderness that are accompanied by dysuria and urinary urgency and frequency, although it is more accurately diagnosed based on the presence of these symptoms along with bacteriuria and acute renal infection (Sobel and Kaye 2005) . AP was formerly treated largely on an inpatient basis, but a recent trend towards outpatient management of this condition has been noted (Czaja et al 2007) . As seen in cUTI, the most common pathogen causing AP is Escherichia coli (Nicolle 1997; Czaja et al 2007) .
The role of fl uoroquinolones in the management of genitourinary infections
Currently available fl uoroquinolones that are approved by the US Food and Drug Administration (FDA) for the treatment of cUTI and/or AP include ciprofl oxacin, levofl oxacin, norfl oxacin, and ofl oxacin. The fl uoroquinolones gemifl oxacin and moxifl oxacin are not approved for either condition. Gatifl oxacin was awarded FDA approval for the management of cUTI and AP, but this agent was withdrawn from the US market in 2006. Levofl oxacin, approved by the US FDA in 1996, is the S enantiomer of the racemate ofl oxacin. The S enantiomer of ofl oxacin displays antibacterial activity that is approximately 2 orders of magnitude greater than that of the R enantiomer; this enhanced activity is due to greater binding to and saturation of the binding site on the DNA gyrase enzyme (Morrissey et al 1996) . Studies of ofl oxacin were not included in the present analysis.
The Infectious Diseases Society of America (IDSA) has published guidelines for the management of acute uncomplicated cystitis and AP (Warren et al 1999) . For cases of AP that are manageable on an outpatient basis using oral antimicrobial therapy, the IDSA recommends a fl uoroquinolone as the preferred empiric therapy, with trimethoprim/sulfamethoxazole (TMP/SMX) offered as an alternative. In patients that are to be hospitalized, the guidelines recommend the use of intravenous therapy with a fl uoroquinolone, an aminoglycoside with or without ampicillin, or an extended-spectrum penicillin with or without an aminoglycoside. After such patients are stabilized, the IDSA recommends that the course of treatment be completed with an oral fl uoroquinolone or oral TMP/SMX. Alternatives are recommended for each of the above patient populations if the infecting organism is known to be a Grampositive coccus. Recommended fi rst-line agents for the treatment of uncomplicated cystitis include a fl uoroquinolone or TMP/SMX, depending on the local rate of TMP/SMX resistance in E. coli. IDSA is currently working towards assembling guidelines for the treatment of cUTI, and publication is anticipated in late 2008. The European Association of Urology (EAU) has published guidelines that include recommendations for cUTI, which advise the use of fl uoroquinolones with mainly renal excretion when empiric therapy is necessary. The EAU recommends avoiding TMP/SMX as fi rst-line treatment because of the increasingly high prevalence of resistance to that antimicrobial agent (Grabe et al 2008) .
Fluoroquinolone resistance
Fluoroquinolones have been extensively used in the management of genitourinary infections, especially acute uncomplicated cystitis. While fl uoroquinolone resistance in uropathogens was once rare, resistance in E. coli has emerged and continues to increase. Fluoroquinolone resistance occurs through multiple mechanisms including chromosomal point mutations in the genes encoding DNA gyrase and/or topoisomerase iv, mutations that cause decreased expression of outer membrane proteins (OMPs), alterations in the lipopolysaccharide (LPS) component of the cell envelope, and enhanced fl uoroquinolone effl ux by effl ux pumps such as AcrAB (Chenia et al 2006; Chang et al 2007) . Plasmid-borne resistance has also recently been discovered, and is caused by protection of DNA gyrase and topoisomerase IV by Qnr-like proteins, including QnrA (Chenia et al 2006) . Surveillance of urinary isolates collected between 1989 and 1997 found that fl uoroquinolone resistance in E. coli was essentially nonexistent during this time frame (Gupta et al 1999a; Gupta et al 1999b) . More recently, results of the North American Urinary Tract Infection Collaborative Alliance (NAUTICA) study, a multicenter surveillance study performed between 2003 and 2004 in the US and Canada, reported that overall resistance rates to ciprofl oxacin and levofl oxacin were 5.5% and 5.1%, respectively (Zhanel et al 2006) . Similar increases in fl uoroquinolone resistance have been noted in the setting of AP (Czaja et al 2007) . Also, among the emerging extendedspectrum beta-lactamase (ESBL)-producing E. coli, higher rates of fl uoroquinolone resistance have been reported. In China, levofloxacin resistance among ESBL-producing E. coli was reported in 86% of isolates (Xiong et al 2002) . In the US, one healthcare system reported that 56% of ESBL-producing E. coli and Klebsiella pneumoniae were resistant to fl uoroquinolones (Lautenbach et al 2001) .
Levofl oxacin pharmacology
Levofloxacin possesses activity against a variety of uropathogens, including E. coli (Davis and Bryson 1994) . The pharmacokinetics of levofl oxacin have been reviewed elsewhere, and a comprehensive evaluation of levofl oxacin's pharmacokinetics is beyond the scope of this review (Fish and Chow 1997) . The bioavailability of levofl oxacin is 100%, although absorption is delayed in the presence of food; the degree of protein binding ranges from 24 to 38%. Levofl oxacin displays linear pharmacokinetics, and an elimination half-life of 7.6 hours after multiple doses of 500 mg. The primary route of elimination is renal, with approximately 71% of a dose eliminated as unchanged drug within 24 hours. Tissue distribution is extensive; urinary levofl oxacin concentrations have been reported to be as high as 128-343 mg/L (the corresponding plasma maximum concentration (C max ) after a single 500 mg dose ranges from 4.5 to 5.2 mg/L) (Langtry and Lamb 1998) . Levofl oxacin also attains adequate penetration into the prostate, with a mean 2.96:1 prostate: plasma concentration ratio, and this agent has demonstrated success in the management of chronic bacterial prostatitis, including equivalent effi cacy to ciprofl oxacin (Drusano et al 2000; Bundrick et al 2003; Naber et al 2008) . The urinary excretion of levofl oxacin (84%) is higher than that of ciprofl oxacin (43%), gatifl oxacin (80%), gemifl oxacin (28%), and moxifl oxacin (20%) (Naber 2001) . Renal clearance of levofl oxacin (but not the plasma C max ) is reduced in the presence of renal impairment.
Few current guidelines describing the optimal treatment of cUTI and AP are available, and the role of levofl oxacin in comparison to alternate antimicrobials (including other fl uoroquinolones) in the management of these conditions must be further defi ned. The objective of this review is to provide a summary of the clinical effi cacy and safety of levofl oxacin in the treatment of cUTI and AP.
Methods
The PubMed search engine was used to query the National Library of Medicine database using the following search terms: "fluoroquinolone," "levofloxacin," "complicated urinary tract infection," "complicated UTI," "cystitis," "pyelonephritis," "urinary tract infection," and "UTI." This query was also limited to English-language publications. The search criteria were chosen to maximize the sensitivity of the search. The same search criteria were used to query the Cochrane Database of Clinical Trials and the Clinical Trials.gov database. We included all English-language publications of either randomized controlled trials or analytical observational studies of the effi cacy of levofl oxacin in treating cUTI and/or AP that were published before February 1, 2008. We excluded studies performed in pediatric patients or that included no comparator group. For each publication, the authors' defi nition of cUTI and AP were used. The citations of all included publications were also considered for inclusion in this review. All publications were assessed for potential duplication of reported data.
For each of the included publications, two authors extracted data on the study design and methods, the defi nitions of key variables (cUTI, AP, microbiologic eradication, and clinical cure), timing of outcome assessments, effi cacy and safety results, infecting pathogens, and the presence and/or development of antibiotic resistance. Data extraction was conducted in this manner so as to evaluate not only the safety and effi cacy but also the generalizability of the studies to general practice.
Results

Study selection
The PubMed query yielded 385 publications. Of these, fi ve publications met the inclusion and exclusion criteria. However, one of these publications reported the fi ndings of a subset of patients (those with AP) and these data were also subsequently published with the results of the full trial (Klausner et al 2007; Peterson et al 2008) . Thus, only the latter publication was included in this review (Peterson et al 2008) . Of the publications that were excluded, 86% were excluded because they were not human subjects-based research (including, for example, systematic reviews), did not include levofl oxacin as a study drug, or were not evaluating therapies for cUTI or AP.
The query of the Cochrane Database of Clinical Trials yielded 55 publications. Of these, eight studies were not included because levofl oxacin was not evaluated, seven were excluded because they were not studies of cUTI or AP, 13 were non-English publications, and the remaining 27 studies had already been identifi ed for consideration in the PubMed query. Similarly, the ClinicalTrials.gov query yielded 60 registered trials (some on-going). Of these trials, 47 were not studies of cUTI or AP, four were conducted in pediatric patients, fi ve were studies not including levofl oxacin, and one was an uncontrolled study. Only three trials were identifi ed as having met inclusion and exclusion criteria. The fi ndings of these trials were published, either in whole or in part, in the publications identifi ed through PubMed. Thus, the summary data available through ClinicalTrials.gov were not included in this review. Review of the cited publications yielded one additional, previously unidentifi ed publication that met inclusion and exclusion criteria.
Five publications met all inclusion and exclusion criteria and are included in this review (Klimberg et al 1998; Richard et al 1998a, b; Peng 1999; Peterson et al 2008) . Table 1 summarizes the design of the trials reported in these publications. All fi ve publications reported the fi ndings of randomized controlled trials. One reported the results of two such trials (Richard et al 1998b) ; thus six trials were described among the fi ve publications. We should also note that three of the publications included in this review arise from two trials. More specifi cally, data from two trials for the subset of AP patients were published in one publication (Richard et al 1998b) and the data pertaining to the cUTI patients from each of these trials were published separately (Klimberg et al 1998; Richard et al 1998a) . From this point forward, we will consider these three publications as presenting the results of four distinct trials.
Overview of study designs
Three trials were conducted in the US (Klimberg et al 1998; Richard et al 1998b; Peterson et al 2008) , two trials in the US and Canada (Richard et al 1998b) , and one trial was conducted in Taiwan (Peng 1999) . The latter was also the only single-center trial. Only two publications specifi cally stated that the targeted sample size was selected to show equivalence within a margin of 15% (Richard et al 1998a; Peterson et al 2008) . One of these publications did not achieve the sample size targeted by their power calculation (Richard et al 1998a) . The remaining trials, which were all of smaller sample sizes, did not specifi cally describe the statistical power, sample size, or margin of equivalence that the trial was designed to target.
The defi nition of cUTI varied across the four trials including these patients. The trials performed by Peng and Peterson et al stated only that a diagnosis of cUTI was required, although females in the latter trial were also required to have at least one of the following complicating factors: neurogenic bladder or urinary retention; partial obstruction, renal tumor or fi brosis, distorted urethral structure; and/or intermittent catheterization (Peng 1999; Peterson et al 2008) . The studies of cUTI published by Klimberg et al and Richard et al required that all subjects possess an anatomic or functional abnormality of the urinary tract and at least one of the following symptoms: urgency frequency, dysuria, hematuria, or fever or history of fever (Klimberg et al 1998; Richard et al 1998a) . Klimberg et al also required that patients present with a baseline urinary sample with more than fi ve urinary white blood cells/high-power fi eld (Klimberg et al 1998) . Three trials also required that study participants present with 10 5 or more colony-forming units (cfu)/mL of at least one species of uropathogen (Klimberg et al 1998; Richard et al 1998a; Peterson et al 2008) , although Peterson et al excluded patients with more than two species of uropathogen present at baseline (Peterson et al 2008) .
Four trials included AP patients. In three of the trials, the defi nitions of AP were similar and required that patients present with 10 5 or more cfu/mL of at least one species of uropathogen and two or more of the following symptoms: fever, fl ank pain or costovertebral angle tenderness, peripheral white blood cell count (WBC) more than 12,500/mm 3 or 10% or greater bands, and/or WBC casts in the urine, or, in the case of Peterson et al a positive antibody-coated bacteria test (Richard et al 2002; Peterson et al 2008) . Similar to the defi nition of cUTI, Peterson et al required that subjects with AP have at least one of the following symptoms: urgency frequency, dysuria, hematuria, or fever or history of fever (Peterson et al 2008) . In contrast, Peng required only a diagnosis of AP (Peng 1999) . All trials assessed the outcomes of microbiologic eradication and clinical success. These defi nitions were similar across all trials (Table 1) .
In each of the six trials, another fl uoroquinolone was selected as the comparator treatment (ciprofl oxacin in three trials, lomefl oxacin in two trials, and ofl oxacin in one trial). One trial allowed patients to be administered either oral or intravenous formulations. The effi cacy and safety results of this trial were not stratifi ed by formulation, although 97% of the intention to treat group were started on an oral formulation of either levofl oxacin or the comparator (Peterson et al 2008) . The fi ve remaining trials evaluated oral administration of levofl oxacin. Of these, four trials were specifi cally limited to outpatients and/or patients deemed appropriate candidates for oral therapy (Klimberg et al 1998; Richard et al 1998a, b) . Five trials specifi cally included in their defi nitions of cUTI and AP that patients' urine cultures at the time of enrollment must contain at least 10 5 cfu/mL of a uropathogen (Klimberg et al 1998; • Cured (complete resolution of the signs and symptoms associated with cUTI)
• Improved (incomplete resolution of signs and symptoms and no requirement for further antibiotic therapy) • Cured (resolution of signs and symptoms associated with active disease)
• Improved (incomplete resolution of signs and symptoms but no need for additional antibiotic therapy)
Days 3-5 of therapy Post-therapy: 5-9 days after completion of therapy Long-term follow-up: 4-6 weeks after therapy a Publications reports the fi ndings of two trials. Abbreviations: AP, acute pyelonephritis; cUTI, complicated urinary tract infection; RCT, randomized controlled trial; cfu, colony-forming units.
spp., and Enterococcus spp. While not all studies reported the frequency with which these organisms were isolated, among those that did, K. pneumoniae was isolated on average in 16% of subjects, while the remaining uropathogens were all isolated in 10% or less of subjects. Among the studies that reported species-specifi c microbiologic eradication rates, eradication failed on average in 7% of cases caused by E. coli within levofl oxacin-treated subjects (Klimberg et al 1998; Richard et al 1998a; Peterson et al 2008) . Peterson et al reported that levofl oxacin non-susceptible bacteria were isolated from 6% of levofl oxacin-treated subjects, and that no acquired resistance was observed (Peterson et al 2008) . In their cUTI trial, Richard et al (1998a) reported that 9.8% of isolates tested were not susceptible to levofl oxacin (Richard et al 1998a) . These were the only publications to provide these data. As may be expected, the usage of urinary catheters was observed in a number of patients in the included trials. All of the included studies allowed the inclusion of catheterized patients, but only 2 of the studies reported the total number of these patients, which constituted approximately 5% of the subjects enrolled in these trials (Klimberg et al 1998; Peterson et al 2008) . Only one of the trials reported outcomes based on catheter usage. Peterson et al reported a signifi cantly worse microbiologic eradication in the 68 catheterized patients compared to those without catheters (74.1% vs 89.0%; 95% CI: −26.6% to −3.3%).
Clinical response
Clinical success was observed to range from 82.6% to 93% when measured after the completion of therapy (Table 2) . Again, Peng (1999) measured clinical effi cacy mid-treatment and observed a clinical success rate of 90%. Statistical testing of the differences in clinical effi cacy was only reported in three publications, and none of these reported any signifi cant difference between the levofl oxacin and comparator groups (Richard et al 1998a; Peng 1999; Peterson et al 2008) . In the remaining two publications, reported clinical effi cacy rates were higher for levofl oxacin than for the comparator (Klimberg et al 1998; Richard et al 1998b) .
Adverse events
Only Peterson et al (2008) reported the occurrence of serious adverse events (17 events in levofl oxacin-treated study subjects). While not all events were detailed in the publication, one allergic reaction and one death were reported. The death was not found to be treatment-related. Adverse event rates were similar for levofl oxacin and comparators in all 1998a, b; Peterson et al 2008) . Four of these trials excluded subjects with previous infections with organisms known to be resistant to any study medication (Klimberg et al 1998; Richard et al 1998a, b) . The fi fth excluded subjects if the UTI was caused by a pathogen resistant to either study medication (Peterson et al 2008) .
Four trials also excluded patients with decreased renal function. Peng excluded patients with renal failure (and other extremely severe underlying diseases) (Peng 1999) . Of the two trials described in Richard et al, one excluded all patients with a creatinine clearance less than 50 mL/min and the second excluded those with a creatinine clearance less than 20 mL/min (Richard et al 1998b) . In the latter trial, dosing was altered for those with a creatinine clearance between 20 and 50 mL/min. This same exclusion criteria (creatinine clearance of less than 20 mL/min) and altered dosing scheme was also applied in the study by Klimberg et al (Klimberg et al 1998) . In both publications, no data were provided as to the number of patients receiving altered dosing, nor were the effi cacy and safety results reported within this subset of subjects. Richard et al's cUTI trial also excluded patients with creatinine clearance less than 50 mL/min (Richard et al 1998a) .
Microbiologic response
Microbiologic eradication rates for levofloxacin were high in all trials. When assessed after the completion of therapy, eradication rates ranging from 79.8% to 95.3% were observed (Table 2) . These rates were not statistically signifi cantly different from that of the comparator treatments. Peng evaluated microbiologic effi cacy only on day 5 of a 10-day course of levofl oxacin and observed an eradication rate of 90%, which was also not signifi cantly different from that of the comparator (Peng 1999) . Richard et al reported relapse rates from the two trials described in that publication; at 4-6 weeks post-therapy, microbiologic relapse was observed in 13% of levofl oxacin-treated subjects and in 6.5% of comparator-treated (ciprofl oxacin or lomefl oxacin) study subjects. The difference was not statistically significant (Richard et al 1998b) . In their cUTI trial, Richard et al (1998a) reported a relapse rates of 9% in the levofl oxacintreated group at 4-6 weeks post-therapy, though 38% of the relapse cases were asymptomatic.
All publications provided information regarding the uropathogens that were most frequently isolated, and in all E. coli was the most commonly isolated (average = 61%).
Other commonly isolated pathogens included K. pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, Enterobacter
Levofl oxacin for complicated UTI and pyelonephritis publications. Only one publication specifi cally reported that no statistically signifi cant differences in individual adverse event rates were found between treatment groups (Peterson et al 2008) . The most commonly observed adverse events across all of the trials include: headache, diarrhea, dyspepsia, nausea, dyspnea, vaginitis, fl atulence, and dizziness. Laboratory test abnormalities were infrequently reported. Klimberg et al (1998) reported that changes in clinical laboratory results occurred infrequently and were comparable across groups. Peng (1999) described patients receiving levofl oxacin who experienced elevated alanine aminotransferase, potassium, blood urea nitrogen, and hemoglobin, but these laboratory changes were not attributed to levofl oxacin therapy. No other studies described laboratory value alterations.
Acute pyelonephritis versus complicated UTI
Four of the trials included in this review included patients with cUTI. However, two of these trials included patients with AP, and did not provide results stratifi ed by infection. Of these two studies, that of Peng (1999) consisted primarily of AP patients (16/20 in the levofl oxacin arm and 19/26 in the ofl oxacin arm), while Peterson et al (2008) enrolled primarily cUTI patients (391/537 in the levofl oxacin arm and 391/556 in the ciprofl oxacin arm). The average levofl oxacin effi cacy rates for the two publications reporting effi cacy for cUTI alone was 93.5% for microbiologic eradication and 92.6% for clinical success (Klimberg et al 1998; Richard et al 1998a) . While Peterson et al did not report stratifi ed effi cacy results, a second publication by the authors (that was not included in this review due to duplicity) reports the results for AP patients alone. This publication also found levofl oxacin to be equivalent to the comparator (ciprofl oxacin) in both safety and effi cacy (Klausner et al 2007) . The average levofl oxacin effi cacy rates for this publication and Richard et al's report of two AP trials were 88.3% for microbiologic eradication and 88.5% for clinical success. Also noteworthy is that Peterson et al (2008) is the only trial of high-dose, short duration levofl oxacin therapy. This trial observed effi cacy rates that were 12.8% lower on average for microbiologic eradication and 9.2% lower on average for clinical success than reported by the other publications. As described above, this was also the only trial to report the occurrence of serious adverse events among levofl oxacin-treated study subjects.
Discussion
The objective of this review was to provide a summary of the existing effi cacy and safety data pertaining to the use of levofl oxacin for the treatment of cUTI and AP. While our search of the literature revealed only fi ve publications meeting the criteria for inclusion, all reported generally high microbiologic and clinical effi cacy rates with minimal occurrences of serious adverse events. Despite this, the paucity of data in this area leaves several questions as to the generalizability of these trials.
The US FDA approves medications for the indication of urinary tract infections, including pyelonephritis, under two categories: (1) uncomplicated urinary tract infections and (2) complicated urinary tract infections and pyelonephritis. The trials included in this review used defi nitions generally consistent with this classifi cation. In contrast to this, the IDSA has utilized a relatively more complex categorization scheme that recommends the use of the following categories in the evaluation of anti-infectives for urinary tract Data are presented from the microbiologically evaluable study subjects; effi cacy not reported for intention to treat or modifi ed intention to treat groups. No end of therapy endpoint assessed. Data presented was collected on day 5 of therapy. e Publication reports the fi ndings of two trials; average effi cacy presented here. No statistical comparisons reported; however, microbiologic and clinical effi cacy rates for levofl oxacin were higher than for the comparators. Abbreviations: AP, acute pyelonephritis; cUTI, complicated urinary tract infection.
infections: (1) acute uncomplicated UTI in women, (2) acute uncomplicated pyelonephritis, (3) complicated UTI and UTI in men, (4) asymptomatic bacteriuria, and (5) recurrent UTI (antimicrobial prophylaxis) (Rubin et al 1992) . While the FDA acknowledges that AP can be either an uncomplicated or complicated disease, it justifi es the aggregation of all AP with cUTI by noting that antibiotic dosing regimens for these conditions are generally similar (US Department of Health and Human Services et al 1998). Nevertheless, clinical and/or microbiologic responses may vary between patients with different complicating factors, including such factors as physical obstruction of the urinary tract, male gender, and immunosuppression. These differences may stem from the need for additional interventional therapies to ensure the resolution of the infection. For example, cUTI patients with anatomical abnormalities may require surgery, and for those with neurogenic bladders, catheterization may be necessary to manage urination (Matsumoto et al 2001; Neal 2008) .
Studies of cUTI included in this review generally did not present effi cacy results stratifi ed according to the specifi c complicating factor(s). One exception is the trial performed by Peterson et al (2008) , which reported signifi cantly different microbiologic eradication rates among the catheterized and non-catheterized patients. These results suggest that the presence of catheters may infl uence outcomes in these studies, and stratifi cation of results by catheter usage is warranted. We agree with others who have recommended that studies including patients with cUTI should report results stratifi ed according to specifi c patient characteristics, since patients with cUTI present with a heterogeneous collection of factors that make their infection complicated (Naber 1999 ).
All of the clinical studies presented compared levofl oxacin with another fl uoroquinolone. All studies reported similar microbiologic and clinical responses for these comparators. No data are available regarding a comparison of levofl oxacin with other classes of antimicrobials. In general, this may be due to a lack of suitable oral alternatives. While direct comparisons are lacking, it has been noted that similar microbiologic success rates ranging from 71%-91% have been reported in trials using beta-lactams and monobactams (piperacillin/tazobactam, ceftriaxone, aztreonam, ceftazidime), carbapenems (imipenem, meropenem, ertapenem) and aminoglycosides (amikacin) (Melekos et al 1991; Nowe 1994; Cox et al 1995; Wells et al 2004) . It is not possible to directly compare the results of these studies to the included levofl oxacin studies, but crude effi cacy rates were similar. Additional research using non-fl uoroquinolone comparators would provide not only direct comparisons of effi cacy, but would also provide for direct comparisons in safety profi les, which may vary to a greater extent between antimicrobial classes.
Levofl oxacin was generally well-tolerated in all of the reviewed trials; this is consistent with what has been observed in other settings at the currently approved doses (Anderson and Perry 2008) . A pooled analysis of patients with respiratory tract infections who were prescribed levofl oxacin 500 mg or 750 mg found that patients receiving both doses experienced a similar rate of adverse events during treatment, and the specifi c adverse events observed were similar to those in the trials reviewed here (Khashab et al 2006) . Additional adverse events not commonly reported in the reviewed publications, but that have been reported in association with levofl oxacin, include photosensitivity, QTc prolongation, hypersensitivity, convulsions, Clostridium diffi cile-associated diarrhea, and tendon rupture; many of these adverse reactions are rarely reported and have been associated with other fl uoroquinolones (Anderson and Perry 2008) . A comprehensive review of adverse events associated with fl uoroquinolone use is not included here; the reader is referred to a recent review of this topic (Mehlhorn and Brown 2007) .
Two of the trials that we reviewed included patients who received altered levofl oxacin doses based upon renal function, although results were not stratifi ed according to the dose received (Klimberg et al 1998; Richard et al 1998b ). An inherent difference in clinical or microbiologic response would not be expected in these patient groups, assuming that dosing according to renal function was performed appropriately. However, further evidence of the effi cacy of the various approved dosing regimens of levofl oxacin is needed. Similarly, the trial by Peterson et al (2008) did not report outcomes that were stratifi ed according to whether patients received oral or intravenous therapy. Based on levofl oxacin's oral bioavailability of 100%, we do not expect that patients receiving oral levofl oxacin would experience poorer outcomes than those receiving intravenous therapy; however, receipt of intravenous therapy may be a marker of more severe illness (eg, bacteremic patients) and thus a more thorough analysis of effi cacy that is stratifi ed by the route of administration is warranted.
The majority of the patients included in the trials described in this review presented with infections of moderate severity, and most studies included only patients who received oral therapy on an outpatient basis. The clinical and microbiologic effi cacy of levofl oxacin in patients with more severe illness (including hospitalized patients) requires further study. Furthermore, larger studies are needed so that levofl oxacin's effi cacy can be evaluated among patients infected with organisms other than E. coli, since the incidence of antimicrobial resistance in urinary tract infections caused by these pathogens is not well-described, and cUTI and AP are frequently caused by pathogens other than E. coli (Nicolle 1997) .
Furthermore, few studies provided meaningful information regarding the development of fl uoroquinolone resistance. Although fl uoroquinolone resistance in such uropathogens as E. coli remains somewhat rare in the US, the prevalence of such resistance is undoubtedly increasing. Regional variations in the prevalence of levofl oxacin resistance have already been identifi ed within the US, where the prevalence of resistance varies from 3.7% in New England to 9.1% in the Mid-South region (David et al 2005) . Peterson et al (2008) was the only publication to report data on resistance that emerged during the course of therapy, though they reported zero occurrences of this event. Fluoroquinolone-resistant E. coli has also been isolated in the rectal fl ora of patients who received ciprofl oxacin for acute uncomplicated cystitis; thus, evaluating resistance in urinary isolates alone may be insuffi cient (Gupta et al 2005) . With the recent proliferation of TMP/SMX-resistant E. coli, fluoroquinolones have frequently become the recommended empiric therapy of choice for acute uncomplicated cystitis (Le and Miller 2001; Warren 2001) . In fact, a recent study found that fl uoroquinolones had replaced TMP/SMX nationwide as the preferred fi rst-line antimicrobial for uncomplicated cystitis (Kallen et al 2006) . Unfortunately, the long-term viability of this strategy in the face of increasing fl uoroquinolone resistance is uncertain, and investigations of fl uoroquinolone-sparing regimens for cUTI and AP, using agents such as TMP/SMX, are needed (Kallen et al 2006; Gupta et al 2007) . The future use of fl uoroquinolones in the management of cUTI and AP is also threatened by the ongoing increase in the number of these infections that are caused by ESBL-producing Enterobacteriaceae, which tend to display cross-resistance to fl uoroquinolones (Muratani and Matsumoto 2006; Baudry et al 2008) . Furthermore, E. coli isolates may harbor resistance-conferring mutations yet appear to be fully-susceptible according to susceptibility breakpoint standards established by the Clinical and Laboratory Standards Institute (Komp Lindgren et al 2003) . New trials that examine levofl oxacin in the setting of cUTI and/or AP should include data regarding the prevalence of resistance (whether it is present in the original infecting isolate or develops during fl uoroquinolone therapy), as it is a mitigating factor in treatment failure, and ongoing surveillance of antimicrobial resistance in uropathogens is of paramount importance.
In the case of uncomplicated urinary tract infections, significant research has led to reduced durations of antimicrobial therapy in patients with these infections. Reducing unnecessarily long durations of therapy is one aim of the judicious antimicrobial movement, which aims to reduce the evolutionary selective pressures that drive the emergence and growing prevalence of antibiotic resistance. In 2007, the US FDA approved a higher dose, shorter duration levofl oxacin regimen for cUTI and AP. We identifi ed only one trial, sponsored by Ortho-McNeil Pharmaceuticals, Inc., in which this therapy was evaluated. Although both microbiologic and clinical effi cacy results were slightly lower for this regimen (750 mg daily for 5 days) than had been reported in other trials using longer durations of lower-dose therapy, this trade-off may be acceptable in patients with less severe disease and may help to limit the increasing development of fl uoroquinolone resistance.
Conclusions
Levofl oxacin has demonstrated high rates of microbiologic and clinical success, with outcomes similar to those obtained by comparator fl uoroquinolones in the included trials. All of the available fl uoroquinolones possess activity against common uropathogens, including E. coli, and most of these agents display favorable pharmacokinetics in the setting of UTI. Alternatives to the fl uoroquinolones for the treatment of cUTI and AP include penicillins, cephalosporins, and TMP/SMX; little data regarding the comparative effi cacy of these agents is available. It is diffi cult to assess the generalizability of studies of cUTI and/or AP because of the lack of a standardized defi nition of cUTI, a high degree of variability in study design, and the level of stratifi cation with which data are reported. An important clinical outcome that was not adequately reported in the majority of these publications was the development of antimicrobial resistance while receiving therapy. This may be an important distinguishing factor among antimicrobials. Ongoing surveillance for fl uoroquinolone resistance among uropathogens is needed so that these data can be applied in the empiric therapy decision-making process. Furthermore, more research is needed to determine optimal treatment durations and dosing regimens for antibiotics in the treatment of cUTI and AP. Rational antibiotic use for high-incidence infections, such as the UTIs, are critical to the control of increasing antibiotic resistance (David et al 2005) . Although levofl oxacin has been associated with favorable outcomes in patients with AP and cUTI, further comparative trials are needed to establish the role of levofl oxacin in comparison to alternative antimicrobial classes in the management of these infections.
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